摘要
背景:神经母细胞瘤是婴儿期最常见的颅外实体瘤。大多数儿童在诊断时都有弥漫性疾病,骨髓是最常见的转移部位。虽然已经定义了几种预后因素(即年龄,分期,组织学,复发性遗传异常),但确定用于疾病随访和治疗监测的非侵入性生物标志物确实仍然是临床需求。 microRNAs(miRNAs)表达的异常调控已经牵连到几种恶性肿瘤中。 目标:在这篇小型综述中,我们描述了肿瘤和循环中神经母细胞瘤中miRNA的最新发现,特别关注那些涉及肿瘤进展和耐药性的研究。此外,我们将讨论使用特定的miRNA作为这种肿瘤的潜在治疗工具。 结果:已经鉴定出几种miRNA在原发性肿瘤中下调或上调,并与MYCN扩增,分化,传播和化疗耐药性有关。有关循环miRNA的文献中很少有证据可以作为液体活检的潜在生物标志物。 结论:鉴别用于无创诊断,危险分层,治疗监测和肿瘤随访的体液标记正在获得越来越多的兴趣,特别是在儿科领域。 miRNAs是神经母细胞瘤生物标记物的合适候选物,但需要进一步的研究来拓展有关它们在这种恶性肿瘤中的作用的知识,以设计miRNAs介导的治疗方法.
关键词: 神经母细胞瘤,microRNAs,外来体,生物标志物,治疗,液体活组织检查。
Current Medicinal Chemistry
Title:MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential
Volume: 25 Issue: 5
关键词: 神经母细胞瘤,microRNAs,外来体,生物标志物,治疗,液体活组织检查。
摘要: Background: Neuroblastoma is the most common extracranial solid tumor in infancy. The majority of children have a disseminated disease at diagnosis with bone marrow as the most common site of metastasis. Although several prognostic factors have been defined (i.e. age, stage, histology, recurrent genetic anomalies), the identification of non-invasive biomarkers for disease follow-up and therapy monitoring is indeed still a clinical need. Aberrant regulation of microRNAs (miRNAs) expression has been implicated in several malignancies.
Objectives: In this mini-review, we describe the recent findings about miRNAs in neuroblastoma, both in the tumor and circulation, with particular focus on those involved in tumor progression and drug resistance. Furthermore, we will discuss the use of specific miRNAs as potential therapeutic tools in this tumor.
Results: Several miRNAs have been identified to be down- or up-regulated in primary tumors and have been associated with MYCN amplification, differentiation, dissemination and chemoresistance. Little evidence is available in the literature about circulating miRNAs which are of particular interest as potential biomarkers for liquid biopsy.
Conclusion: Identification of body-fluid markers for non-invasive diagnosis, risk stratification, treatment monitoring and tumor follow-up, is gaining growing interest, especially in the pediatric field. miRNAs are suitable candidates as biomarkers in neuroblastoma but further investigations are needed to expand knowledge regarding their role in this malignancy to design specific approaches of miRNAs-mediated therapies.
Export Options
About this article
Cite this article as:
MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential, Current Medicinal Chemistry 2018; 25 (5) . https://dx.doi.org/10.2174/0929867324666171003120335
DOI https://dx.doi.org/10.2174/0929867324666171003120335 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery New Trends in Fiber-Optic Chemical and Biological Sensors
Current Analytical Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry The Interaction of GLUT1 and FOXM1 Leads to a Poor Prognosis in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Dietary Fat and Hypertension: A Novel Approach Through the Proteolytic Regulatory Enzymes of the Renin-Angiotensin-System
Cardiovascular & Hematological Agents in Medicinal Chemistry Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Potential Role of Calcium/Calmodulin-dependent Protein Kinase II to Angiogenesis Mediated Pathological Changes Seen in Osteoarthritis
Current Angiogenesis (Discontinued) Hydrogen Sulphide: Biopharmacological Roles in the Cardiovascular System and Pharmaceutical Perspectives
Current Medicinal Chemistry CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Current Neuropharmacology